Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CRO Marcus Jewell sold 9,928 shares of the company's stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $10.66, for a total value of $105,832.48. Following the completion of the sale, the executive directly owned 404,345 shares in the company, valued at approximately $4,310,317.70. The trade was a 2.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Marcus Jewell also recently made the following trade(s):
- On Monday, November 16th, Marcus Jewell sold 12,462 shares of Cellebrite DI stock. The stock was sold at an average price of $11.55, for a total value of $143,936.10.
- On Thursday, November 12th, Marcus Jewell sold 393 shares of Cellebrite DI stock. The stock was sold at an average price of $13.31, for a total transaction of $5,230.83.
- On Friday, August 21st, Marcus Jewell sold 12,562 shares of Cellebrite DI stock. The stock was sold at an average price of $11.24, for a total transaction of $141,196.88.
Cellebrite DI Stock Down 4.2%
Shares of NASDAQ:CLBT opened at $10.65 on Wednesday. The company has a market cap of $2.66 billion, a P/E ratio of 44.38, a P/E/G ratio of 1.41 and a beta of 1.06. The business has a fifty day simple moving average of $11.58 and a 200-day simple moving average of $13.17. Cellebrite DI Ltd. has a 52 week low of $9.58 and a 52 week high of $19.39.
Analysts Set New Price Targets
CLBT has been the topic of a number of research reports. Lake Street Capital cut their price objective on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, August 14th. Needham & Company LLC increased their price target on Cellebrite DI from $12.50 to $14.00 and gave the stock a "buy" rating in a research report on Thursday, November 12th. DA Davidson reaffirmed a "buy" rating and set a $15.00 price target on shares of Cellebrite DI in a research note on Tuesday, September 15th. JPMorgan Chase & Co. decreased their target price on Cellebrite DI from $16.00 to $15.00 and set an "overweight" rating on the stock in a report on Friday, November 13th. Finally, Weiss Ratings raised Cellebrite DI from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $14.75.
View Our Latest Stock Analysis on Cellebrite DI
Hedge Funds Weigh In On Cellebrite DI
A number of institutional investors and hedge funds have recently bought and sold shares of CLBT. PNC Financial Services Group Inc. grew its holdings in shares of Cellebrite DI by 59.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company's stock worth $103,000 after purchasing an additional 2,785 shares in the last quarter. Elevation Wealth Partners LLC boosted its holdings in Cellebrite DI by 93.3% in the third quarter. Elevation Wealth Partners LLC now owns 5,833 shares of the company's stock valued at $66,000 after acquiring an additional 2,816 shares during the last quarter. Pacer Advisors Inc. boosted its stake in Cellebrite DI by 91.1% in the first quarter. Pacer Advisors Inc. now owns 7,607 shares of the company's stock valued at $105,000 after acquiring an additional 3,626 shares during the last quarter. Moody National Bank Trust Division increased its stake in shares of Cellebrite DI by 7.6% in the 2nd quarter. Moody National Bank Trust Division now owns 60,691 shares of the company's stock valued at $886,000 after acquiring an additional 4,284 shares during the last quarter. Finally, Quantinno Capital Management LP bought a new stake in shares of Cellebrite DI in the 1st quarter valued at $150,000. Institutional investors own 45.88% of the company's stock.
Cellebrite DI Company Profile
(
Get Free Report)
Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company's offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.